ClinicalTrials.gg
CompletedNCT02994394Updated Jun 28, 2021Results posted

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

A Phase 1 interventional study of OPC-41061 in Healthy Adult Male, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-28.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Male
01

Study summary

To assess the bioequivalence of OPC-41061 OD tablets and OPC-41061 conventional tablets at 15 and 30 mg in healthy adult male subjects.

02

Conditions studied

  • Healthy Adult Male
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of at least 50.0 kg
  • [body weight in kg / (height in m)2] of at least 17.6 kg/m2 and less than 25.0 kg/m2
  • Judged by the investigator or subinvestigator to be capable of providing written prior to the start of any trial-related procedures and capable of complying with the trial procedures for this study.

Exclusion criteria

Exclusion Criteria:

  • Judged by the investigator,subinvestigator, or sponsor to have a abnormality in results of the screening examination (including a notable deviation from the site's standard values) or a medical history that could place the subject at risk or affect the evaluation of drug absorption, distribution, metabolism, or excretion
  • History of alcohol or drug dependence or abuse within 2 years prior to the trial
  • History or current infection with hepatitis or acquired immunodeficiency syndrome (AIDS) or carrier of positive surface antigen (HBsAg), anti- virus (HCV), (HIV), or syphilis based on the results of the Treponema pallidum (TP) antibody test or rapid plasma reagin (RPR) test
  • History of any severe drug allergy
  • Positive results in alcohol screening test or urine drug screening test at time of screening examination or trial site admission
  • Use of any other medicinal product (IMP) within 120 days prior to Period 1 IMP administration
  • Consumption of any food or beverage containing St. John's wort within 14 days prior to Period 1 IMP administration
  • Consumption of any food or beverage containing grapefruit, Seville orange, or star fruit within 7 days prior to Period 1 IMP administration
  • Judgment by the investigator or subinvestigator that the subject should not participate in the study for any other reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    OPC41061(15 mg) disintegrating tablet with water

    OPC41061 (15 mg) orally disintegrating tablet is administered with water.

    Drug: OPC-41061

  • Experimental
    OPC-41061(15 mg) disintegrating tablet without water

    OPC41061 (15 mg) orally disintegrating tablet is administered without water.

    Drug: OPC-41061

  • Experimental
    OPC-41061(15 mg) conventional tablet with water

    OPC-41061 (15 mg) conventional tablet is administered with water.

    Drug: OPC-41061

  • Experimental
    OPC41061(30 mg) disintegrating tablet with water

    OPC41061 (30 mg) orally disintegrating tablet is administered with water.

    Drug: OPC-41061

  • Experimental
    OPC-41061(30 mg) disintegrating tablet without water

    OPC41061 (30 mg) orally disintegrating tablet is administered without water.

    Drug: OPC-41061

  • Experimental
    OPC-41061(30 mg) conventional tablet with water

    OPC-41061 (30 mg) conventional tablet is administered with water.

    Drug: OPC-41061

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Tolvaptan

    Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.

    Time frame: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose

  2. Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan

    Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.

    Time frame: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose

07

Results

Posted Jun 28, 2021

Participant flow

This single-center, open-label, randomized, 3-period 3-way, crossover study using 2 different formulations and 2 different dosing regimens investigated bioequivalence between tolvaptan orally disintegrating (OD) and conventional tablets in 84 healthy adult male subjects in 2 cohorts. Bioequivalence between the OD and conventional 15 mg tablets was investigated in Cohort 1. In Cohort 2, bioequivalence between the OD and conventional 30 mg tablets was investigated.

Period 1 (Days 1 to 3)
Participant flow — Period 1 (Days 1 to 3)
MilestoneCohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional TabletCohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet
Started141414141414
Completed141413141414
Not completed001000
Withdrew: Adverse event001000
Period 2 (Days 4 to 6)
Participant flow — Period 2 (Days 4 to 6)
MilestoneCohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional TabletCohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet
Started141413141414
Completed141313141314
Not completed010010
Withdrew: Adverse event010010
Period 3 (Days 7 and 8)
Participant flow — Period 3 (Days 7 and 8)
MilestoneCohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional TabletCohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With WaterCohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without WaterCohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet
Started141313141314
Completed141313141314
Not completed000000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Tolvaptan

Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.

Time frame:
Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Tolvaptan
ng/mLCohort 1: 15 mg Conventional TabletCohort 1: 15 mg OD Tablet Without WaterCohort 1: 15 mg OD Tablet With WaterCohort 2: 30 mg Conventional TabletCohort 2: 30 mg OD Tablet Without WaterCohort 2: 30 mg OD Tablet With Water
Maximum Plasma Concentration (Cmax) of Tolvaptan131 ± 71.0149 ± 72.6125 ± 63.1203 ± 72.7218 ± 56.0198 ± 54.7
PrimaryArea Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan

Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.

Time frame:
Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan
ng*h/mLCohort 1: 15 mg Conventional TabletCohort 1: 15 mg OD Tablet Without WaterCohort 1: 15 mg OD Tablet With WaterCohort 2: 30 mg Conventional TabletCohort 2: 30 mg OD Tablet Without WaterCohort 2: 30 mg OD Tablet With Water
Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan697 ± 440674 ± 361685 ± 3921120 ± 3341130 ± 3061110 ± 312

Adverse events

Collected over Treatment-emergent adverse events were collected during the treatment period (8 days). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 15 mg Conventional Tablet0/41 (0%)0/41 (0%)1/41 (2.4%)
Cohort 1: 15 mg OD Tablet Without Water0/41 (0%)0/41 (0%)1/41 (2.4%)
Cohort 1: 15 mg OD Tablet With Water0/41 (0%)0/41 (0%)2/41 (4.9%)
Cohort 2: 30 mg Conventional Tablet0/42 (0%)0/42 (0%)1/42 (2.4%)
Cohort 2: 30 mg OD Tablet Without Water0/42 (0%)0/42 (0%)0/42 (0%)
Cohort 2: 30 mg OD Tablet With Water0/41 (0%)0/41 (0%)0/41 (0%)
Most frequent other events
Most frequent other events
EventCohort 1: 15 mg Conventional TabletCohort 1: 15 mg OD Tablet Without WaterCohort 1: 15 mg OD Tablet With WaterCohort 2: 30 mg Conventional TabletCohort 2: 30 mg OD Tablet Without WaterCohort 2: 30 mg OD Tablet With Water
NauseaGastrointestinal disorders0/411/410/410/420/420/41
VomitingGastrointestinal disorders0/410/411/410/420/420/41
Alanine Aminotransferase IncreasedInvestigations1/410/411/411/420/420/41

Baseline characteristics

Safety analysis set: all subjects that received at least 1 dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean24.4 ± 4.323.5 ± 4.824.0 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female000
Male424284
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
Japanese424284
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Total
Japan424284
08

Study locations

1 site
  • Kyusyu Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Feb 2017, 1 month.

Results were first posted in Jun 2021, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 15, 2016
StartActual
Jan 6, 2017
Primary completionActual
Feb 28, 2017
CompletionActual
Feb 28, 2017
Results first posted
Jun 28, 2021
Last update
Jun 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02994394
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Jan 6, 2017
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017
Results posted
Jun 28, 2021
Last update
Jun 28, 2021

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion